On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Metroplex Clinical Research Center

InstitutionResearch output, impact & collaborations

Metroplex Clinical Research Center is a institution indexed in ScholarIQ from OpenAlex.

What is known about Metroplex Clinical Research Center?

ScholarIQrecord summary

Metroplex Clinical Research Center is a research organisation in Dallas, US. OpenAlex records 531 works and 43,298 citations for it. 42 researchers list it as their most recent affiliation.

How many works does Metroplex Clinical Research Center have?

ScholarIQindexed works

Metroplex Clinical Research Center has 531 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Metroplex Clinical Research Center have?

ScholarIQcitation count

Metroplex Clinical Research Center has 43,298 citations in the OpenAlex counts ScholarIQ stores.

How many researchers are at Metroplex Clinical Research Center?

ScholarIQresearcher count

Metroplex Clinical Research Center has 42 researchers in the ScholarIQ index.

What is the average h-index at Metroplex Clinical Research Center?

ScholarIQavg h-index

Metroplex Clinical Research Center has an average h-index of 87 in OpenAlex.

What is the ROR of Metroplex Clinical Research Center?

ScholarIQror

The ROR for Metroplex Clinical Research Center is on the source record.

What is the OpenAlex record for Metroplex Clinical Research Center?

ScholarIQopenalex

The OpenAlex for Metroplex Clinical Research Center is on the source record.

Who are the most-cited researchers behind Metroplex Clinical Research Center?

ScholarIQtop researchers by citations
1
Stanley Cohen · Macrophage Migration Inhibitory Factor
460 works41,566 citations
2
Roy Fleischmann · Rheumatoid Arthritis Research and Therapies
490 works32,688 citations

What are the most-cited papers on Metroplex Clinical Research Center?

ScholarIQmost cited works
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann, Joel M. Kremer, John J. Cush, Hendrik Schulze‐Koops, Carol A. Connell, John Bradley, David Gruben, Gene V. Wallenstein, Samuel H. Zwillich, Keith S. Kanik
New England Journal of Medicine. 20121,038 CitationsOPEN ACCESS
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A. García Meijide, Sylke Wagner, Šárka Forejtová, Samuel H. Zwillich, David Gruben, Tamás Koncz, Gene V. Wallenstein, Sriram Krishnaswami, John Bradley, Bethanie Wilkinson
New England Journal of Medicine. 2012944 CitationsOPEN ACCESS
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee, Roy Fleischmann, Stephen Hall, Bethanie Wilkinson, John Bradley, David Gruben, Tamás Koncz, Sriram Krishnaswami, Gene V. Wallenstein, Chuanbo Zang, Samuel H. Zwillich, Ronald van Vollenhoven
New England Journal of Medicine. 2014779 CitationsOPEN ACCESS
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Edward Keystone, Joel M. Kremer, Cristiano A. F. Zerbini, Myrna Cardiel, Stanley Cohen, Peter Nash, Yeong Wook Song, Dana Tegzová, Bradley T. Wyman, David Gruben, Birgitta Benda, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, John Bradley, Carol A. Connell, and the ORAL Scan Investigators
Arthritis & Rheumatism. 2013583 Citations
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
Joel M. Kremer, Zhanguo Li, Stephen Hall, Roy Fleischmann, Mark C. Genovese, E. Martín‐Mola, John D. Isaacs, David Gruben, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, Tamás Koncz, Richard J. Riese, John Bradley
Annals of Internal Medicine. 2013450 Citations

How much of the research on Metroplex Clinical Research Center is open access?

ScholarIQopen access share
43%OPEN ACCESS
Gold
0%
Green
0%
Hybrid
0%
Bronze
43%
Closed
57%

Related on ScholarIQ

470M+ articles · 14-day free trial